Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Clofarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 8/20 | 0.69 |
| ▸ | CD99 | P14209 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofarabine SCHEMBL12595105 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL17752021 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL1467619 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL4570563 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL5975001 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL12139443 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL23620882 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL15468200 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL9040 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL10026375 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202792-B2 | CD99 inhibitors and their uses | GEORGETOWN UNIVERSITY (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | SONIC MASTER LTD (VG) | 2021-07-01 | — | — | US | disclosed |
| US-10987372-B2 | Anti-hepatoma-virus agent | KAGOSHIMA UNIVERSITY (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10933068-B2 | Modulators of DUX4 for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2021-03-02 | — | — | US | disclosed |
| US-10696972-B2 | Method for improving learning | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200123190-A1 | 5'-POSITION DIBENZYL MONOPHOSPHATE DERIVATIVE OF NUCLEOSIDE-BASED ANTICANCER AGENT OR ANTIVIRUS AGENT | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-23 | — | — | US | disclosed |
| US-20190298727-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LIMITED (VG) | 2019-10-03 | — | — | US | disclosed |
| US-20190262370-A1 | CD99 Inhibitors and Their Uses | GEORGETOWN UNIVERSITY (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190070207-A1 | ANTI-HEPATOMA-VIRUS AGENT | KAGOSHIMA UNIVERSITY (JP) | 2019-03-07 | — | — | US | disclosed |
| US-10184142-B2 | Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients | PLASMIA BIOTECH, S.L. (ES) | 2019-01-22 | — | — | US | disclosed |
| US-7947824-B2 | Process for preparing purine nucleosides | GENZYME CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| US-7772206-B2 | Methods and compositions for the treatment of autoimmune disorders using clofarabine | GENZYME CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090297478-A1 | Methods and Compositions for the Treatment of Lupus Using Clofarabine | WOOD CHRISTOPHER B | 2009-12-03 | — | — | US | disclosed |
| US-20090286971-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | GENZYME CORPORATION | 2009-11-19 | — | — | US | disclosed |
| WO-2009074253-A2 | CLOFARABINE PHOSPHOLIPID DERIVATIVES | HEIDELBERG PHARMA AG (DE) | 2009-06-18 | — | — | WO | disclosed |
| US-20090155211-A1 | multiple sclerosis; side effect reduction | WOOD CHRISTOPHER B | 2009-06-18 | — | — | US | disclosed |
| EP-2070938-A1 | Clofarabine dietherphospholipid derivatives | Heidelberg Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-7528247-B2 | Process for preparing purine nucleosides | GENZYME CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1261350-B1 | METHODS FOR SYNTHESIZING 2-CHLORO-9-(2-DEOXY-2-FLUORO-BETA-D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE | SOUTHERN RES INST (US) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262370-A1 | CD99 Inhibitors and Their Uses | CD99, CD74, LY96 | PDE2A 2071/4885ADORA3 3772/4885PDE4D 3163/4885 |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | DDX21, MBNL1, MECP2 | PDE2A 946/4885ADORA3 4350/4885PDE4D 379/4885 |
| US-11202792-B2 | CD99 inhibitors and their uses | CD99, CD209, CD79B | PDE2A 1920/4885ADORA3 2611/4885PDE4D 3574/4885 |
| US-20090297478-A1 | Methods and Compositions for the Treatment of Lupus Using Clofarabine | SSB, BCL9, IL2 | PDE2A 1405/4885ADORA3 2670/4885PDE4D 2601/4885 |
| US-20090155211-A1 | multiple sclerosis; side effect reduction | MGMT, TPMT, SLC16A1 | PDE2A 1064/4885ADORA3 2567/4885PDE4D 1917/4885 |
| US-10933068-B2 | Modulators of DUX4 for regulation of muscle function | DDX21, MBNL1, MECP2 | PDE2A 903/4885ADORA3 4336/4885PDE4D 360/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | PDE2A 2234/4885ADORA3 999/4885PDE4D 2010/4885 |
| US-10696972-B2 | Method for improving learning | NT5E, ADORA1, ENTPD5 | PDE2A 942/4885ADORA3 5/4885PDE4D 184/4885 |
| US-10987372-B2 | Anti-hepatoma-virus agent | HAVCR2, HDGF, HDGFL3 | PDE2A 4650/4885ADORA3 2205/4885PDE4D 4594/4885 |
| US-20190298727-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | DDX21, MBNL1, MECP2 | PDE2A 903/4885ADORA3 4336/4885PDE4D 360/4885 |
| US-20190070207-A1 | ANTI-HEPATOMA-VIRUS AGENT | HAVCR2, HDGF, HDGFL3 | PDE2A 4650/4885ADORA3 2205/4885PDE4D 4594/4885 |
| US-20090286971-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | PNP, SAMHD1, NUDT1 | PDE2A 1481/4885ADORA3 114/4885PDE4D 372/4885 |
| US-20200123190-A1 | 5'-POSITION DIBENZYL MONOPHOSPHATE DERIVATIVE OF NUCLEOSIDE-BASED ANTICANCER AGENT OR ANTIVIRUS AGENT | DUT, DPYD, TYMP | PDE2A 1446/4885ADORA3 537/4885PDE4D 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.